[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558981":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":44,"responsibleParty":60,"collaborators":62,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":42,"enrollmentInfo":77,"targetDuration":42,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":42,"overallStatus":46,"whyStopped":42,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Massachusetts General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Romosozumab","ACTIVE_COMPARATOR","romosozumab",[13],"Drug: Romosozumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Romosozumab and Teriparatide","romosozumab and teriparatide",[13,18],"Drug: Teriparatide",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","romosozumab 210 milligrams monthly",[9,15],[25],"Evenity",{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Teriparatide","teriparatide 20 micrograms daily",[15],[31],"Forteo",[33],{"name":34,"affiliation":35,"role":36},"Benjamin Leder, MD","MGH","PRINCIPAL_INVESTIGATOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"Aparna Patnaik, BA","CONTACT","617-726-6129",null,"apatnaik1@mgh.harvard.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Boston","Massachusetts","02114","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-71.05977,42.35843,{"lat":56,"lon":55},[59],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":36,"investigatorFullName":34,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Professor of Medicine",[63],{"name":64,"class":65},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH","100558981","phase-4-combined-anabolic-therapy-100558981",false,"NCT06558188","Combined Anabolic Therapy","Combined Anabolic Therapy Study","CAT","Inclusion Criteria:\n\n* women aged 45+\n* postmenopausal\n* osteoporotic with high risk of fracture\n\nExclusion Criteria:\n\n* no significant previous use of bone health modifying treatments\n* known congenital or acquired bone disease other than osteoporosis\n* significant renal disease, liver disease, cardiopulmonary disease, or psychiatric disease\n* abnormal calcium or parathyroid hormone level\n* serum vitamin D \\\u003C20 ng\u002FdL\n* anemia (hematocrit \\\u003C32%)\n* history of malignancy (except non-melanoma skin carcinoma)\n* excessive alcohol use or substance abuse\n* known contraindications to romosozumab or teriparatide",true,"FEMALE","45 Years",{"count":78,"type":79},50,"ESTIMATED","INTERVENTIONAL",[82],"PHASE4","In this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmenopausal osteoporosis.",[85,86],"Osteoporosis, Postmenopausal","Osteoporosis","2026-04-14",{"date":89,"type":90},"2026-04-17","ACTUAL",{"date":92,"type":90},"2025-02-03",{"date":94,"type":79},"2028-04-01",{"name":5,"class":6},1]